Danish cancer specialist Genmab (Nasdaq: GMAB) has announced the granting of European approval to its development partner, Novartis (NOVN: VX), for Kesimpta (ofatumumab).
Kesimpta is a targeted B-cell therapy being developed and marketed worldwide by Novartis under a license agreement with Genmab.
The therapy has shown superior efficacy with a similar safety profile compared with teriflunomide, an oral multiple sclerosis (MS) therapy sold by Sanofi (Euronext: SAN) as Aubagio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze